176 related articles for article (PubMed ID: 24652177)
1. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia.
Buendía JA; Vallejos C; Pichón-Rivière A
Biomedica; 2013; 33(3):411-7. PubMed ID: 24652177
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer.
Aboutorabi A; Hadian M; Ghaderi H; Salehi M; Ghiasipour M
Glob J Health Sci; 2014 Aug; 7(1):98-106. PubMed ID: 25560346
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
Chen W; Jiang Z; Shao Z; Sun Q; Shen K
Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
8. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.
Lang HC; Chen HW; Chiou TJ; Chan AL
J Med Econ; 2016 Oct; 19(10):923-7. PubMed ID: 27135256
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
Nguyen AQ; Tran OTM; Nguyen PK; Nguyen HT
PLoS One; 2024; 19(3):e0300474. PubMed ID: 38489305
[TBL] [Abstract][Full Text] [Related]
10. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
[TBL] [Abstract][Full Text] [Related]
11. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
Skedgel C; Rayson D; Younis T
Value Health; 2009; 12(5):641-8. PubMed ID: 19490562
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
15. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Candon D; Healy J; Crown J
Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
[TBL] [Abstract][Full Text] [Related]
16. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
[TBL] [Abstract][Full Text] [Related]
18. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.
Hall PS; Hulme C; McCabe C; Oluboyede Y; Round J; Cameron DA
Pharmacoeconomics; 2011 May; 29(5):415-32. PubMed ID: 21504241
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.
McKeage K; Lyseng-Williamson KA
Pharmacoeconomics; 2008; 26(8):699-719. PubMed ID: 18620462
[TBL] [Abstract][Full Text] [Related]
20. Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?
Skedgel C; Rayson D; Younis T
Ann Oncol; 2013 Jul; 24(7):1834-1840. PubMed ID: 23510987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
